{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T22:41:21Z","timestamp":1775688081129,"version":"3.50.1"},"reference-count":23,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2009,9,1]],"date-time":"2009-09-01T00:00:00Z","timestamp":1251763200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Psychosomatics"],"published-print":{"date-parts":[[2009,9]]},"DOI":"10.1016\/s0033-3182(09)70848-5","type":"journal-article","created":{"date-parts":[[2011,12,18]],"date-time":"2011-12-18T18:02:36Z","timestamp":1324231356000},"page":"538-542","source":"Crossref","is-referenced-by-count":11,"title":["Prolonged Psychosis Associated With Interferon Therapy in a Patient With Hepatitis C: Case Study and Literature Review"],"prefix":"10.1016","volume":"50","author":[{"given":"Yi-Chun","family":"Cheng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chun-Chih","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ai-Sheng","family":"Ho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nan-Ying","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/S0033-3182(09)70848-5_bib0005","first-page":"341","volume":"72","author":"Hepatitis","year":"1997","journal-title":"Weekly Epidemiological Record"},{"key":"10.1016\/S0033-3182(09)70848-5_bib0010","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1056\/NEJM199811193392101","article-title":"Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C: Hepatitis Interventional Therapy Group","volume":"339","author":"McHutchison","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/S0033-3182(09)70848-5_bib0015","doi-asserted-by":"crossref","first-page":"225","DOI":"10.2165\/00063030-200115040-00003","article-title":"Combination therapy with interferonalpha and ribavirin for hepatitis C: practical treatment issues","volume":"15","author":"Collier","year":"2001","journal-title":"BioDrugs"},{"key":"10.1016\/S0033-3182(09)70848-5_bib0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta8390","article-title":"Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation","volume":"8","author":"Shepherd","year":"2004","journal-title":"Health Technol Assess"},{"key":"10.1016\/S0033-3182(09)70848-5_bib0025","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1111\/j.1572-0241.2005.00282.x","article-title":"A randomized trial of pegylated interferon alpha-2b plus ribavirin in the retreatment of chronic hepatitis C","volume":"100","author":"Jacobson","year":"2005","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/S0033-3182(09)70848-5_bib0030","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1097\/00131746-200303000-00002","article-title":"Comprehensive review of hepatitis C for psychiatrists: risks, screening, diagnosis, treatment, and interferon-based therapy complications","volume":"9","author":"Crone","year":"2003","journal-title":"J Psychiatr Pract"},{"key":"10.1016\/S0033-3182(09)70848-5_bib0035","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1046\/j.1440-1819.2000.00754.x","article-title":"Psychiatric symptoms related to interferon therapy for chronic hepatitis C: clinical features and prognosis","volume":"54","author":"Hosoda","year":"2000","journal-title":"Psychiatry Clin Neurosci"},{"key":"10.1016\/S0033-3182(09)70848-5_bib0040","first-page":"82","article-title":"Schizophrenia: Full National Clinical Guideline on Core Interventions in Primary and Secondary Care","year":"2003","journal-title":"London, UK, Royal College of Psychiatrists and the British Psychological Society"},{"key":"10.1016\/S0033-3182(09)70848-5_bib0045","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reaction","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/S0033-3182(09)70848-5_bib0050","doi-asserted-by":"crossref","first-page":"S203","DOI":"10.1055\/s-2003-45131","article-title":"Neurotransmitter changes by interferon-alpha and therapeutic implications","volume":"36","author":"Schaefer","year":"2003","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/S0033-3182(09)70848-5_bib0055","first-page":"787","article-title":"Neuropsychiatric symptoms related to interferon alpha","volume":"40","author":"Malyszczak","year":"2006","journal-title":"Psychiatra Polska"},{"key":"10.1016\/S0033-3182(09)70848-5_bib0060","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/S0033-3182(99)71208-9","article-title":"Neuropsychiatric toxicity associated with cytokine therapy","volume":"40","author":"Lerner","year":"1999","journal-title":"Psychosomatics"},{"key":"10.1016\/S0033-3182(09)70848-5_bib0065","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1345\/aph.1C266","article-title":"Psychosis associated with interferon-alfa therapy for chronic hepatitis B","volume":"37","author":"Tamam","year":"2003","journal-title":"Ann Pharmacother"},{"key":"10.1016\/S0033-3182(09)70848-5_bib0070","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1176\/appi.psy.44.5.417","article-title":"Treatment of interferon-induced psychosis in patients with comorbid hepatitis C and HIV","volume":"44","author":"Hoffman","year":"2003","journal-title":"Psychosomatics"},{"key":"10.1016\/S0033-3182(09)70848-5_bib0075","first-page":"1101","article-title":"Psychosis in a methadonesubstituted patient during interferon-alpha treatment of hepatitis C","volume":"95","author":"Sch\u00e4fer","year":"2000","journal-title":"Addiction"},{"key":"10.1016\/S0033-3182(09)70848-5_bib0080","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/S0924-9338(01)00553-3","article-title":"An interferon-alpha-induced psychotic disorder in a patient with chronic hepatitis C","volume":"16","author":"Bozikas","year":"2001","journal-title":"Eur Psychiatry"},{"key":"10.1016\/S0033-3182(09)70848-5_bib0085","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1097\/01.jcp.0000227348.59912.5d","article-title":"Persistent psychosis after treatment with interferon-alpha: a case report","volume":"26","author":"Telio","year":"2006","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/S0033-3182(09)70848-5_bib0090","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1590\/S1413-86702006000600010","article-title":"Psychosis during peg-interferon-alpha2a and ribavirin therapy: case report","volume":"10","author":"Quarantini","year":"2006","journal-title":"Braz J Infect Dis"},{"key":"10.1016\/S0033-3182(09)70848-5_bib0095","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.3748\/wjg.v13.i16.2379","article-title":"An extremely rare case of delusional parasitosis in a chronic hepatitis C patient during pegylated interferon alpha-2b and ribavirin treatment","volume":"13","author":"Robaeys","year":"2007","journal-title":"World J Gastroenterol"},{"key":"10.1016\/S0033-3182(09)70848-5_bib0100","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1055\/s-2007-984390","article-title":"Chronic paranoid psychosis and dementia following interferon-alpha treatment of hepatitis C: a case report","volume":"40","author":"Drozdz","year":"2007","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/S0033-3182(09)70848-5_bib0105","doi-asserted-by":"crossref","first-page":"581","DOI":"10.4088\/JCP.v65n0420b","article-title":"Ribavirin may be an important factor in IFN-induced neuropsychiatric effects","volume":"65","author":"Asnis","year":"2004","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/S0033-3182(09)70848-5_bib0110","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2165\/00003495-200666020-00003","article-title":"Psychiatric and substance use disorders in individuals with hepatitis C: epidemiology and management","volume":"66","author":"Loftis","year":"2006","journal-title":"Drugs"},{"key":"10.1016\/S0033-3182(09)70848-5_bib0115","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1016\/j.pnpbp.2005.03.006","article-title":"Interferon-induced depression: strategies in treatment","volume":"29","author":"Asnis","year":"2005","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"}],"container-title":["Psychosomatics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0033318209708485?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0033318209708485?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,27]],"date-time":"2018-11-27T17:28:30Z","timestamp":1543339710000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0033318209708485"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,9]]},"references-count":23,"aliases":["10.1176\/appi.psy.50.5.538"],"journal-issue":{"issue":"5","published-print":{"date-parts":[[2009,9]]}},"alternative-id":["S0033318209708485"],"URL":"https:\/\/doi.org\/10.1016\/s0033-3182(09)70848-5","relation":{},"ISSN":["0033-3182"],"issn-type":[{"value":"0033-3182","type":"print"}],"subject":[],"published":{"date-parts":[[2009,9]]}}}